Immunotherapy Regimen for EGFR-Mutated Non–Small-Cell Lung Cancer

Despite high initial response rates, patients with epidermal growth factor receptor (EGFR)–mutated non–small-cell lung cancer (NSCLC) develop resistance to EGFR tyrosine kinase inhibitors (TKIs), and median progression-free survival (PFS) ranges from 9 to 19 months with first-line treatment. Upon progression, most patients receive chemotherapy. There has been interest in integrating immunotherapy into treatment, however, single-agent immunotherapy has minimal efficacy.

In the previously reported IMpower150 trial, the addition of the PDL1 inhibitor atezolizumab to the combination of bevacizumab, carboplatin, and paclitaxel improved PFS, including in a heterogeneous subset of patients with EGFR mutations and ALK translocations, all of whom had…